Compass Therapeutics (CMPX) News Today $3.49 +0.21 (+6.40%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$3.45 -0.04 (-1.17%) As of 05:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Compass Therapeutics to Participate in Upcoming September Investor EventsAugust 26 at 8:00 AM | globenewswire.comCompass Therapeutics (CMPX) Rated ‘Outperform’ amid Clinical Pipeline DevelopmentAugust 19, 2025 | insidermonkey.comHC Wainwright Has Negative Outlook of CMPX FY2025 EarningsAugust 16, 2025 | marketbeat.comEquities Analysts Offer Predictions for CMPX FY2025 EarningsAugust 16, 2025 | marketbeat.comCompass Therapeutics Announces Public Offering to Raise $112.5MAugust 14, 2025 | msn.comWedbush Issues Negative Estimate for CMPX EarningsAugust 14, 2025 | marketbeat.comCompass Therapeutics 33.3M share Spot Secondary priced at $3.00August 13, 2025 | msn.comCompass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral CapitalAugust 13, 2025 | marketbeat.comGuggenheim Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock PriceAugust 13, 2025 | marketbeat.comWedbush Equities Analysts Reduce Earnings Estimates for CMPXAugust 13, 2025 | marketbeat.comCompass Therapeutics Announces Pricing of Upsized $120 Million Public OfferingAugust 12, 2025 | globenewswire.comCompass Therapeutics price target raised to $12 from $10 at GuggenheimAugust 12, 2025 | msn.comCompass Therapeutics Announces Proposed Public OfferingAugust 12, 2025 | globenewswire.comCompass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Estimates By $0.01 EPSAugust 12, 2025 | marketbeat.comCompass Therapeutics Faces Financial Risks Amid Global Economic Uncertainty and Trade TensionsAugust 12, 2025 | msn.comCompass Therapeutics rises after pipeline updatesAugust 11, 2025 | msn.comCompass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate UpdateAugust 11, 2025 | globenewswire.comCompass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025August 8, 2025 | globenewswire.comCompass Therapeutics (CMPX) Expected to Announce Earnings on MondayAugust 5, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of "Buy" from AnalystsAugust 5, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Buy" by BrokeragesJuly 11, 2025 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Raymond James FinancialJuly 1, 2025 | marketbeat.comCMPX Compass Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comSG Americas Securities LLC Buys 545,767 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)June 16, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Recommendation of "Buy" by AnalystsJune 16, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLCJune 15, 2025 | marketbeat.comInsider Buying: Compass Therapeutics, Inc. (NASDAQ:CMPX) CEO Buys 10,000 Shares of StockMay 29, 2025 | marketbeat.comCompass Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comCompass Therapeutics, Inc. (NASDAQ:CMPX) CEO Thomas J. Schuetz Purchases 10,000 SharesMay 28, 2025 | insidertrades.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of "Buy" from BrokeragesMay 24, 2025 | marketbeat.comTang Capital Management LLC Has $8.56 Million Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)May 20, 2025 | marketbeat.comMPM Bioimpact LLC Buys 2,926,002 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)May 16, 2025 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Meets ExpectationsMay 14, 2025 | marketbeat.comFY2027 EPS Estimate for Compass Therapeutics Cut by AnalystMay 14, 2025 | marketbeat.comQ2 EPS Estimate for Compass Therapeutics Lowered by AnalystMay 13, 2025 | marketbeat.comEnavate Sciences GP LLC Takes $11.29 Million Position in Compass Therapeutics, Inc. (NASDAQ:CMPX)May 11, 2025 | marketbeat.comStifel Nicolaus Sticks to Its Buy Rating for Compass Therapeutics (CMPX)May 11, 2025 | theglobeandmail.comCompass Therapeutics price target lowered to $10 from $12 at GuggenheimMay 9, 2025 | msn.comCompass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate UpdateMay 8, 2025 | globenewswire.comCompass Therapeutics (CMPX) to Release Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comCompass Therapeutics to Participate in Upcoming May Investor EventsMay 6, 2025 | globenewswire.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 23.4% in AprilMay 5, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires 227,864 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)May 4, 2025 | marketbeat.comHC Wainwright Has Bearish Outlook for CMPX FY2027 EarningsMay 3, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Reduces Stock Position in Compass Therapeutics, Inc. (NASDAQ:CMPX)May 1, 2025 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Receives "Buy" Rating from D. Boral CapitalApril 30, 2025 | marketbeat.comCompass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual MeetingApril 28, 2025 | globenewswire.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Buy" from AnalystsApril 28, 2025 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Given "Buy" Rating at GuggenheimApril 24, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Compass Therapeutics (NASDAQ:CMPX)April 23, 2025 | marketbeat.com Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMPX Media Mentions By Week CMPX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMPX News Sentiment▼0.931.03▲Average Medical News Sentiment CMPX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMPX Articles This Week▼23▲CMPX Articles Average Week Get the Latest News and Ratings for CMPX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Compass Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies IMCR News BHVN News WVE News AUPH News TVTX News EWTX News SDGR News AVDL News ARDX News JANX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMPX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access